Lucijanic Marko, Piskac Zivkovic Nevenka, Busic Nikolina, Stojic Josip, Atic Armin, Derek Lovorka, Krecak Ivan, Barsic Bruno, Luksic Ivica
Division of Hematology, Internal Medicine Department, University Hospital Dubrava, 10000 Zagreb, Croatia.
Scientific Research and Translational Medicine Department, University Hospital Dubrava, 10000 Zagreb, Croatia.
Viruses. 2025 Apr 27;17(5):629. doi: 10.3390/v17050629.
Patients hospitalized due to coronavirus disease 2019 (COVID-19) usually present with severe or critical intensity of symptoms, accompanied by a marked systemic inflammatory response. Classical inflammatory biomarkers, C-reactive protein (CRP), albumin, and red blood cell distribution width (RDW) have previously been reported to be prognostic in hospitalized COVID-19 patients. We performed a retrospective analysis of two large cohorts (2305 and 2328 patients, respectively) of consecutive hospitalized COVID-19 patients with mostly severe and critical symptoms admitted to the tertiary referral center to develop and validate a prognostic score for 30-day mortality based on CRP-to-Albumin-Ratio (CAR), RDW, and age (termed CARRA-VID score). We identified 6 prognostic categories: very low, low, intermediate-1, intermediate-2, high, and very high risk, with corresponding 30-day mortality rates of 2.7%, 10.7%, 30.9%, 47.1%, 61.9%, and 89.7%, respectively. Effective risk stratification was validated in an independent cohort of patients and remained independent of the World Health Organization-defined disease severity and other commonly utilized risk scores. Additional analyses evaluated the score across different time periods dominated by distinct viral variants. We also present a simplified 3-tiered version of the score. A Microsoft Excel Workbook containing the score calculator is provided.
因2019冠状病毒病(COVID-19)住院的患者通常症状严重或危急,伴有明显的全身炎症反应。经典炎症生物标志物,如C反应蛋白(CRP)、白蛋白和红细胞分布宽度(RDW),此前已被报道对COVID-19住院患者具有预后价值。我们对一家三级转诊中心收治的两组连续住院的COVID-19患者(分别为2305例和2328例)进行了回顾性分析,这些患者大多症状严重或危急,旨在基于CRP与白蛋白比值(CAR)、RDW和年龄(称为CARRA-VID评分)制定并验证一个30天死亡率的预后评分。我们确定了6个预后类别:极低、低、中-1、中-2、高和极高风险,对应的30天死亡率分别为2.7%、10.7%、30.9%、47. I%、61.9%和89.7%。有效的风险分层在一个独立的患者队列中得到验证,并且独立于世界卫生组织定义的疾病严重程度和其他常用的风险评分。进一步分析评估了该评分在由不同病毒变体主导的不同时间段的情况。我们还给出了该评分的简化三层版本。提供了一个包含评分计算器的Microsoft Excel工作簿。